---
document_datetime: 2026-01-26 16:59:54
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/levetiracetam-actavis-group-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: levetiracetam-actavis-group-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0865254
conversion_datetime: 2026-02-01 20:29:44.231761
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Levetiracetam Actavis Group

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 22/01/2026                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308189                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority - Accepted C.I.3.z - to update section 4.6 of the SmPC and section 2 of the PL to implement the wording agreed by the CHMP following the outcome of the PSUR procedure EMEA/H/C/PSUSA/00001846/202411. In addition, the MAH took the opportunity to submit editorial updates in section 6 of the Package Leaflet (list of local representatives): change of company name   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000315029 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 19/12/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |             |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IB / EMA/VR/0000256234 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted Type IB C.I.2.a - Update of section 4.8 of the SmPC and section 4 of the PIL to include additional information on signs and symptoms of Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS) following assessment of the same change for the reference product Keppra (EMEA/H/C/WS2722). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to introduce minor changes to the PI (also including a statement that 'this medicine does not require any special storage | 26/06/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| QRD template.   |
|-----------------|